Acute vs Chronic Leukemia: How to Tell Them Apart
Both are malignant clonal proliferations of blood-forming cells that can raise the white count and cause splenomegaly. The dividing line is acuity: acute leukemia is driven by a maturation arrest that floods the marrow with blasts and produces a rapid, marrow-failure presentation, while chronic leukemia is an indolent accumulation of mature-appearing cells, often found incidentally.
How to tell them apart
| Feature | Acute leukemia (ALL, AML) | Chronic leukemia (CLL, CML) |
|---|---|---|
| Cell maturity | Maturation arrest: proliferating blasts that cannot differentiate crowd out normal hematopoiesis | Accumulation of mature or maturing cells — mature B lymphocytes in CLL; a full spectrum of myeloid maturation in CML |
| Blast percentage | >20% blasts in blood or marrow defines 'acute' | Mature cells predominate; CML shows a myelocyte 'bulge' with full myeloid maturation rather than a blast excess |
| Clinical trajectory | Rapid, aggressive onset with prominent symptoms | Indolent course; CLL is often asymptomatic and discovered incidentally on a routine CBC |
| Dominant presentation | Bone marrow failure — anemia (fatigue, pallor), thrombocytopenia (bleeding, petechiae), and neutropenia (infections) — plus leukemic infiltration | Marked lymphocytosis (CLL) or very high WBC with myeloid maturation (CML); in CLL, recurrent infections stem from hypogammaglobulinemia despite a high lymphocyte count |
| Characteristic morphology/markers | ALL blasts are TdT positive; AML shows Auer rods (pathognomonic) and is myeloperoxidase positive | CLL shows fragile 'smudge cells' with CD5+, CD19+, CD23+ B cells; CML shows basophilia/eosinophilia and low leukocyte alkaline phosphatase |
| Typical age | ALL peaks in children (ages 2–5) with a second peak in the elderly; AML is the most common acute leukemia in adults (median age ~68) | CLL median age ~70; CML median age in the mid-60s (~64–67), with a broad peak spanning roughly 45–85 years |
| WBC pattern | Variable — can be high, normal, or low ('aleukemic leukemia' in AML) depending on degree of marrow failure | Typically high — CML often 50,000–200,000; CLL lymphocytosis often exceeds 20,000 and can surpass 100,000 |
The reasoning
Anchor first on cell maturity and blast percentage. A blast count ≥20% in blood or marrow, coupled with a maturation arrest and cytopenias, defines acute leukemia — then subclassify by lineage (TdT+ lymphoid markers for ALL; Auer rods and myeloperoxidase for AML). If instead the elevated count is composed of mature-appearing cells, you are dealing with chronic leukemia: mature CD5+ B lymphocytes with smudge cells point to CLL, whereas a very high WBC with a full spectrum of myeloid maturation, basophilia, and low LAP points to CML confirmed by BCR-ABL1. Trajectory helps arbitrate — an abrupt, symptomatic presentation with marrow failure favors acute disease, while an incidental or indolent course favors chronic disease.
Key tests
- Peripheral smear and blast count: ≥20% blasts confirms acute leukemia; mature lymphocytes with smudge cells suggest CLL, while a full myeloid maturation spectrum with basophilia suggests CML
- Flow cytometry / immunophenotype: TdT+, CD10/CD19 (B-ALL) or CD2/CD3/CD7 (T-ALL) in acute lymphoid disease; CD5+/CD19+/CD23+ with weak monoclonal surface Ig in CLL
- Cytogenetics/FISH and RT-PCR for BCR-ABL1: t(9;22) defines CML (and marks Ph+ ALL); leukocyte alkaline phosphatase is low in CML, distinguishing it from a reactive leukemoid reaction
What they share
- Malignant clonal proliferation of blood-forming cells that can be lymphoid or myeloid in origin
- Frequently produce an elevated WBC count and organomegaly (splenomegaly, hepatosplenomegaly)
- Constitutional 'B symptoms' — fatigue, weight loss, and night sweats — can occur in both
- Both can cause anemia and thrombocytopenia from marrow infiltration
- The Philadelphia chromosome t(9;22)/BCR-ABL1 appears in chronic disease (CML) and in a subset of acute disease (Ph+ ALL), and both benefit from tyrosine kinase inhibitors
Pitfalls
- CML blast crisis (≥20% blasts) resembles and behaves like acute leukemia — don't assume every blast-heavy smear is a de novo acute leukemia
- The Philadelphia chromosome is not exclusive to CML: it also appears in a subset of ALL (Ph+ ALL), so t(9;22) alone doesn't establish chronicity — integrate blast count and immunophenotype
- A high WBC does not mean adequate immunity: CLL patients have abundant but non-functional B cells and hypogammaglobulinemia, causing recurrent infections despite lymphocytosis
- AML can present with a low WBC ('aleukemic leukemia'), so a normal or low count does not exclude acute leukemia — check the marrow
- Very high neutrophil/myeloid counts without infection can be reactive (leukemoid reaction); a low LAP and BCR-ABL1 point to CML rather than a reactive process
Practice this the way the exam tests it — on branching cases where your decisions shape the patient.